To B or not to B, that is the question: Is it time to replace colistin with polymyxin B?

Pharmacotherapy

Volumn 35, Issue 1, 2015, Pages 17-21

  Kassamali, Zahra ^a   Danziger, Larry ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Colistin; Pharmacology; Polymyxin B; Therapeutic use

Indexed keywords

COLISTIMETHATE; COLISTIN; POLYMYXIN B;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG RESEARCH; DRUG SUBSTITUTION; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; QUESTIONNAIRE; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84964270667     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1510     Document Type: Article

References (36)

1. World Health Organization. Antimicrobial resistance: global report on surveillance, 2014. Available from http://apps. who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf. Accessed June 5, 2014.
2. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65.
3. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come with age. Clin Infect Dis 2013;57:877-83.
4. Nation RL, Velkov T, Li J. Colistin and Polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014;59(1):88-94.
5. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
6. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013;57:524-31.
7. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B. Similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21.
8. Thomas AH, Thomas JM, Holloway I. Microbiological and chemical analysis of polymyxin B and polymyxin E (colistin) sulphates. Analyst 1980;105:1068-75.
9. Kassamali Z, Rhomberg PR, Jones RN, Danziger LH, Prince RA. Polymyxin B: can we create a better product? [abstract P1730]. In Final Programme 24th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona). European Society for Clinical Microbiology and Infectious Diseases, 2014.
10. Kassamali Z, Wang W, Jones RN, Rotschafer JC, Danziger LH, Prince RA. Is what you see, what you get? Product variation in clinical and reference formulations of polymyxin B [abstract 1119]. In Final Programme 23rd European Congress of Clinical Microbiology and Infectious Diseases (Berlin). European Society for Clinical Microbiology and Infectious Diseases, 2013.
11. He J, Ledesma KR, Figueroa DA, Lim T, Chow DSL, Tam VH. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 2010;35:308-10.
12. He H, Li JC, Nation RL, et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 2013;68:2311-7.
13. Barnett M, Bushby SRM, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Brit J Pharmacol 1964;23:552-74.
14. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmac Chemother 1967;29:125-35.
15. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8.
16. Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011;89:875-9.
17. Pop-Vicas A, Tacconelli E, Gravenstein S, Lu B, D'Agata EM. Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect Control Hosp Epidemiol 2009;30:325-31.
18. Pop-Vicas AE, D'Agata EM. The rising influx of multidrugresistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005;40:1792-8.
19. Yapa SWS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014;58:2570-9.
20. Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013;68:674-7.
21. Nord NM, Hoeprich PD. Polymyxin B and colistin, a critical comparison. N Engl J Med 1964;270:1030-5.
22. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systemic review of the evidence from old and recent studies. Crit Care 2006;10:R27.
23. Pogue J, Marchaim D, Hayakawa K, Pulluru H, Kaye K. Colistin-associated nephrotoxicity: the impact of definition [abstract 0244]. In Final Programme 24th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona). European Society for Clinical Microbiology and Infectious Diseases, 2014.
24. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014;58:2740-6.
25. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300-3.
26. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exaerbations in adult patients with cystic fibrosis. Thorax 1997;52:987-93.
27. JHP Pharmaceuticals. Coly-Mycin M [Package Insert]. Rochester, MI; 2011.
28. Sobieszcyzk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-9.
29. Farbman L, Goldberg E, Yahav D, Bishara J, Leibovici L, Paul M. No association between colistin daily dose and clinical outcomes with low colistin dosing [abstract eP210]. In Final Programme 24th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona). European Society for Clinical Microbiology and Infectious Diseases, 2014.
30. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J Clin Microbiol 2013;51:1678-84.
31. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013;56:398-404.
32. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extendedinterval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study Clin Infect Dis 2012;54:1720-9.
33. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010;65:2231-7.
34. Crusio R, Rao S, Changawala N, et al. Epidemiology and outcome of infections with carbapenem-resistant gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis 2014;46:1-8.
35. Dubrovskaya Y, Chen T, Scipione MR, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2013;57:5394-7.
36. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;19:1489-94.